Troglitazone | 1696

An antidiabetic thiazolidinedione (TDZ) drug with anti-inflammatory and anti-tumor activities. A potent and selective PPARɣ agonist. The EC₅₀ values for transactivation of human and murine PPARɣ in a cell-based assay are 0.55 and 0.78 µM, respectively.

Troglitazone is an antidiabetic thiazolidinedione (TDZ) drug with anti-inflammatory and anti-tumor activities. A potent and selective PPARɣ agonist.

1696 | Troglitazone DataSheet

Alternate Name/Synonyms: (±)-5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione

Appearance: Off-white solid

Formulation: N/A

CAS Number: 97322-87-7

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₄H₂₇NO₅S

Molecular Weight: 441.54

Cell-Permeable?: Yes

Purity: ≥95% by HPLC

Solubilities: DMSO (25 mg/ml) or Ethanol (25 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A selective PPARɣ agonist

MDL Number: MFCD00878416

PubChem CID: 5591

SMILES: CC1=C(C(=C2CCC(OC2=C1C)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)O

InChi: InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)

InChi Key: GXPHKUHSUJUWKP-UHFFFAOYSA-N